Polyethylene Glycol Losenatide Injection should be injected into the abdomen as directed by the physician. Polyethylene glycol losenatide injection is a long-acting glucagon-like peptide agonist that should be used in conjunction with dietary control and appropriate exercise, either alone or in combination with metformin, for glycemic control in adult patients with type 2 diabetes. The drug should be injected subcutaneously in the abdomen, usually not in the arms or buttocks, and care should be taken to avoid prolonged injections in the same part of the abdomen. The drug should be contraindicated in people who are allergic to the product, in patients with a family history of medullary thyroid carcinoma, medullary thyroid carcinoma, or with multiple endocrine neoplasia syndrome type 2. Adverse reactions such as nausea, vomiting, and diarrhea may occur after administration of the drug. Specific medication should be administered under the guidance of a specialist.